AAIC 2025 Abstract·23 DecTarget Engagement of Lecanemab on CSF Aβ Protofibril Toxic Species in Clarity ADTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecThe Lecanemab Clarity AD Open‐Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48‐Month AnalysisTrial in peopleInterventionsPaper